

April 18, 2007

Ono Pharmaceutical Co., Ltd.  
Public Relations  
Phone: 06 6263 5670  
Fax: 06 6263 2950

### **Announcement of Approval of Staybla<sup>®</sup> Tablets 0.1mg, a Drug for Overactive Bladder**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan, President: Toshiharu Korekane) announced that Staybla<sup>®</sup> Tablets 0.1mg (imidafenacin), a Drug for treatment of Overactive Bladder (OAB), was approved on April 18, 2007.

Staybla<sup>®</sup> Tablets 0.1mg is a drug that was discovered by Kyorin Pharmaceutical Co., Ltd. and co-developed by Kyorin and Ono. It is a novel anticholinergic agent exerting selective antagonist activity against M<sub>3</sub> and M<sub>1</sub> muscarinic subtype receptors, and improves urgency of urination, pollakiuria and urge urinary incontinence associated with OAB. It is expected that this drug can contribute to improvement of the patient QOL of OAB because it exerts high selectivity to the bladder and can therefore reduce dry mouth.

Ono will strive to actively provide the scientific information for proper use of Staybla<sup>®</sup> Tablets 0.1mg and to pursue the market penetration as early as possible through co-marketing with Kyorin.

#### **PRODUCT PROFILE APPROVED**

Trade name	Staybla <sup>®</sup> Tablets 0.1mg
Nonproprietary name	imidafenacin
Classification	A drug for treatment of OAB
Indications	Urgency of urination, pollakiuria and urge urinary incontinence associated with OAB
Dosage and administration	Usually, for adults, Staybla <sup>®</sup> Tablets 0.1mg is orally administered in a single dose of 0.1mg as imidafenacin, twice daily, after each meal in the morning and evening.

#### **< REFERENCE >**

Overactive Bladder (OAB) is a disease based on excessive contraction of bladder smooth muscle and causes symptoms such as urgency of urination, pollakiuria and urge urinary incontinence. According to the epidemiological investigation of Neurogenic Bladder Society, it is estimated that approximately 8.1 million people or 12.4% of male and female over the age of 40 years potentially suffers from OAB in Japan.